Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy

Perisomatic changes in h-channels regulate depressive behaviors following chronic unpredictable stress

(2017) C S Kim et al.   MOLECULAR PSYCHIATRY

Effects of a ketamine metabolite on synaptic NMDAR function

(2017) Kanzo Suzuki et al.   NATURE

Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder

(2016) Brittany Jaso et al.   Current Neuropharmacology

Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity

(2016) Danielle M. Gerhard et al.   DRUG DISCOVERY TODAY

GABA interneurons mediate the rapid antidepressant-like effects of scopolamine

(2016) Eric S. Wohleb et al.   JOURNAL OF CLINICAL INVESTIGATION

NMDAR inhibition-independent antidepressant actions of ketamine metabolites

(2016) Panos Zanos et al.   NATURE

Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants

(2016) Ronald S Duman et al.   NATURE MEDICINE

Effects of memantine on the excitation-inhibition balance in prefrontal cortex

(2016) Nadezhda V. Povysheva et al.   NEUROBIOLOGY OF DISEASE

Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition

(2016) Oliver H. Miller et al.   NEUROPHARMACOLOGY

Essential roles of AMPA receptor GluA1 phosphorylation and presynaptic HCN channels in fast-acting antidepressant responses of ketamine

(2016) K. Zhang et al.   Science Signaling

What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder

(2016) Gerard Sanacora   JAMA Psychiatry

Essential roles of AMPA receptor GluA1 phosphorylation and presynaptic HCN channels in fast-acting antidepressant responses of ketamine

(2016) K. Zhang et al.   Science Signaling

Randomized Proof of Concept Trial of GLYX-13, an N-Methyl-D-Aspartate Receptor Glycine Site Partial Agonist, in Major Depressive Disorder Nonresponsive to a Previous Antidepressant Agent

(2015) SHELDON PRESKORN et al.   Journal of Psychiatric Practice

Rapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors

(2015) Andrea Navarria et al.   NEUROBIOLOGY OF DISEASE

Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABAA Receptors

(2015) Jonathan Fischell et al.   NEUROPSYCHOPHARMACOLOGY

BDNF Release Is Required for the Behavioral Actions of Ketamine

(2015) A. E. Lepack et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function

(2014) Yukitoshi Izumi et al.   NEUROPHARMACOLOGY

Mice Lacking NMDA Receptors in Parvalbumin Neurons Display Normal Depression-Related Behavior and Response to Antidepressant Action of NMDAR Antagonists

(2014) Laura Pozzi et al.   PLoS One

Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses

(2014) E. S. Gideons et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

17β Estradiol increases resilience and improves hippocampal synaptic function in helpless ovariectomized rats

(2014) Teruko M. Bredemann et al.   PSYCHONEUROENDOCRINOLOGY

GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine

(2014) Oliver H Miller et al.   eLife

Scopolamine Rapidly Increases Mammalian Target of Rapamycin Complex 1 Signaling, Synaptogenesis, and Antidepressant Behavioral Responses

(2013) Bhavya Voleti et al.   BIOLOGICAL PSYCHIATRY

Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings)

(2013) Georges Mion et al.   CNS Neuroscience & Therapeutics

Antidepressant Augmentation Using theN-Methyl-d-Aspartate Antagonist Memantine

(2013) Eric G. Smith et al.   JOURNAL OF CLINICAL PSYCHIATRY

Acute Suppression of Spontaneous Neurotransmission Drives Synaptic Potentiation

(2013) E. Nosyreva et al.   JOURNAL OF NEUROSCIENCE

Developmental origin dictates interneuron AMPA and NMDA receptor subunit composition and plasticity

(2013) Jose A Matta et al.   NATURE NEUROSCIENCE

GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects

(2013) Jeffrey Burgdorf et al.   NEUROPSYCHOPHARMACOLOGY

The Role of Eukaryotic Elongation Factor 2 Kinase in Rapid Antidepressant Action of Ketamine

(2012) Lisa M. Monteggia et al.   BIOLOGICAL PSYCHIATRY

Estradiol-induced increase in novel object recognition requires hippocampal NR2B-containing NMDA receptors

(2012) Lindsey C. Vedder et al.   HIPPOCAMPUS

A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder

(2012) Lobna Ibrahim et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Synaptic Dysfunction in Depression: Potential Therapeutic Targets

(2012) R. S. Duman et al.   SCIENCE

Inhibitory control of hippocampal inhibitory neurons

(2012) Simon Chamberland et al.   Frontiers in Neuroscience

Glutamate N-methyl-D-aspartate Receptor Antagonists Rapidly Reverse Behavioral and Synaptic Deficits Caused by Chronic Stress Exposure

(2011) Nanxin Li et al.   BIOLOGICAL PSYCHIATRY

Amyloid- /Fyn-Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease

(2011) E. D. Roberson et al.   JOURNAL OF NEUROSCIENCE

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

(2011) Anita E. Autry et al.   NATURE

Replication of Scopolamine's Antidepressant Efficacy in Major Depressive Disorder: A Randomized, Placebo-Controlled Clinical Trial

(2010) Wayne C. Drevets et al.   BIOLOGICAL PSYCHIATRY

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

(2010) N. Li et al.   SCIENCE

An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder

(2008) Sheldon H. Preskorn et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral–CA1 synapses in hippocampus

(2008) Xiao-lei Zhang et al.   NEUROPHARMACOLOGY

Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors

(2007) Sungho Maeng et al.   BIOLOGICAL PSYCHIATRY

Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus

(2007) Lêda S.B. Garcia et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY